كتاب
Epidemiology and Etiology of AML
| العنوان: | Epidemiology and Etiology of AML |
|---|---|
| المؤلفون: | Juliusson, Gunnar, Lazarevic, Vladimir, Lehmann, Sören |
| المساهمون: | Röllig, Christoph, Ossenkoppele, Gert J. |
| المصدر: | Hematologic Malignancies; pp 1-22 (2021) ; ISSN: 2197-9774 ; ISSN: 2197-9766 |
| بيانات النشر: | Springer Science and Business Media B.V. |
| سنة النشر: | 2021 |
| المجموعة: | Lund University Publications (LUP) |
| مصطلحات موضوعية: | Cancer and Oncology, Benzene, Diagnosis, Exposure, Hereditary conditions, Incidence, Mutations, Prevalence, Secondary AML, Sex, Survival, t-AML |
| الوصف: | Acute myeloid leukemia (AML) is a grave disease with an incidence of 4 per 100,000 a year. It can present in all ages, but the median age is 70 years. One-third of such patients have secondary AML, that is, AML following chemoradiotherapy or a transformation from previous myelodysplastic syndrome (MDS) or myeloproliferative neoplasia. A combination of genetic, epigenetic, and environmental factors may be responsible for the development of most cases of AML. The pathogenesis of AML is characterized by the serial acquisition of somatic mutations and several genes are recurrently mutated in AML. Exposures to benzene, cigarette smoking, pesticides, embalming fluids, accidental or professional ionization radiation, therapeutic radiotherapy, and radioactive I-131 therapy can cause AML with or without a preceding MDS phase. Alkylating agents (e.g., melphalan, cyclophosphamide), topoisomerase-II inhibitors (e.g., etoposide, doxorubicin), and other drugs (e.g., azathioprine) are described to be associated with the development of therapy-related AML (t-AML). Furthermore, about 5–15% of adults and 4–13% of pediatric patients with MDS or AML carry germline pathogenic variants in cancer susceptibility genes. Individuals with clonal hematopoiesis (CHIP) progress to AML at a rate of about 1% per year. Higher age of onset, obesity, previous autoimmune disease, and antecedent MDS or MPN are associated with a risk for developing AML. |
| نوع الوثيقة: | book part |
| اللغة: | English |
| ردمك: | 978-3-030-72678-2 978-3-030-72676-8 3-030-72678-9 3-030-72676-2 |
| العلاقة: | https://lup.lub.lu.se/record/717b7c46-5247-473a-b141-582f8bbe4c68Test; http://dx.doi.org/10.1007/978-3-030-72676-8_1Test; scopus:85106496515 |
| DOI: | 10.1007/978-3-030-72676-8_1 |
| الإتاحة: | https://doi.org/10.1007/978-3-030-72676-8_1Test https://lup.lub.lu.se/record/717b7c46-5247-473a-b141-582f8bbe4c68Test |
| رقم الانضمام: | edsbas.CB0A4017 |
| قاعدة البيانات: | BASE |
| ردمك: | 9783030726782 9783030726768 3030726789 3030726762 |
|---|---|
| DOI: | 10.1007/978-3-030-72676-8_1 |